Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALTEC: Talquetamab and Teclistamab Consolidation in NDMM
NCT06505369Phase 2Recruiting
- Sponsor
- North Estonia Medical Centre
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of talquetamab, teclistamab in multiple myeloma (MM), sponsored by North Estonia Medical Centre. Started Jun 2024; status: recruiting.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06505369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505369.